Search

Displaying results 3811 - 3820 of 9702 in total
  1. Drug

    Mycobacterium w. Vaccine

    go.drugbank.com/drugs/DB15798
    Investigational

    The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii.

  2. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. … As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.

  3. Drug

    BacTRL-spike

    go.drugbank.com/drugs/DB15811
    Investigational

    As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids.

  4. Drug

    Potassium aspartate

    go.drugbank.com/drugs/DB15819
    ApprovedWithdrawn

    Synonyms: L-aspartate potassiumProducts: POTASSIUM L-ASPARTATE
  5. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM.

  6. Drug

    Gam-COVID-Vac

    go.drugbank.com/drugs/DB15848
    Investigational

    The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac Lyo). … Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials.

  7. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established … Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.

  8. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    IMM-101 is a heat-inactivated immune-activating mycobacterial product. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  9. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged

  10. Drug

    RUTI® Vaccine

    go.drugbank.com/drugs/DB15853
    Investigational

    Much like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. … The vaccine has demonstrated a reasonable safety profile and potent stimulation of the immune response against tuberculosis.